Transplant company Magenta plans $100M listing

Stem cell transplant company Magenta Therapeutics Inc. (Cambridge, Mass.) filed to raise up to $100 million in an IPO on NASDAQ. Underwriters are J.P. Morgan, Goldman Sachs, Cowen and Wedbush PacGrow.

Magenta is developing biologics, small molecules and a cell therapy with the aim of broadening the range of patients eligible for stem cell therapy and improving the procedure's efficacy. Its lead program, MGTA-456, is in a Phase II study to treat inherited metabolic diseases; data are due next half. Early next year, the company intends to start a Phase II study of the therapy to treat sickle cell disease...